Phoxillum Approved for Electrolyte Imbalances in CRRT

Phoxillum Approved for Electrolyte Imbalances in CRRT
Phoxillum Approved for Electrolyte Imbalances in CRRT

Baxter announced that the Food and Drug Administration (FDA) has approved Phoxillum Renal Replacement Solutions (BK4/2.5 and B2K4/0) for use in continuous renal replacement therapy (CRRT) to replace plasma volume removed by ultrafiltration, correct electrolyte and acid-base imbalances, and for use in drug poisoning when CRRT is used to remove dialyzable substances.

Phoxillum is the only approved pre-mixed solution containing phosphate in a 5000mL bag. The electrolyte concentrations in the solutions are chosen to restore plasma levels to clinically desired concentrations or maintain plasma levels at the desired concentrations . The bicarbonate present in the solution is used as an alkalinizing buffer to restore acid-base balance to a clinically desirable level.

RELATED: Two Agents Show Promise for Hyperkalemia

Phoxillum is available in a 2-compartment 5000mL bag containing different bicarbonate concentrations. It is anticipated to launch in the second quarter of 2015.

For more information call (800) 422-9837 or visit Baxter.com.